Sulfasalazine

證據等級: L5

預測適應症: 10 個

Sulfasalazine: From Rheumatoid Arthritis/Inflammatory Bowel Disease to Brachydactyly-Syndactyly Syndrome

One-Sentence Summary

Sulfasalazine is a long-established anti-inflammatory/immunomodulatory agent (NF-κB inhibitor combining 5-ASA and sulfapyridine), best known for rheumatoid arthritis and inflammatory bowel disease, though its formal original-indication record is not available in this evidence pack. The TxGNN model's top-ranked prediction is Brachydactyly-Syndactyly Syndrome, a rare congenital skeletal disorder, but this direction is currently supported by 0 clinical trials and 0 publications — it is a pure model output with no mechanistic or empirical backing.

Quick Overview

Item	Content
Original Indication	Not available in structured NZ regulatory data (drug not marketed); per known pharmacology, sulfasalazine is used for rheumatoid arthritis and inflammatory bowel disease/ankylosing spondylitis
Predicted New Indication	Brachydactyly-Syndactyly Syndrome
TxGNN Prediction Score	99.94%
Evidence Level	L5
New Zealand Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (blocking data gap). Based on known information, sulfasalazine is a DMARD-class agent whose antineoplastic/anti-inflammatory efficacy has been demonstrated in rheumatologic and gastrointestinal inflammatory conditions.

Brachydactyly-syndactyly syndrome is a rare congenital skeletal developmental disorder with no established inflammatory or immune-mediated pathology. According to the evidence pack's own repurposing rationale, there is no known mechanistic relationship between sulfasalazine's anti-inflammatory/immunomodulatory activity and this disease's underlying (developmental/genetic) biology.

This top-ranked prediction should be treated as a pure network-embedding signal (TxGNN score, rank 826 among all disease nodes) rather than a biologically grounded hypothesis. It has not been validated by any clinical trial or literature search — both returned zero results.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

New Zealand Market Information

Sulfasalazine currently holds no marketing authorization in New Zealand (0 licenses on record); no product/dosage-form data is available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked TxGNN prediction (Brachydactyly-Syndactyly Syndrome) has no supporting clinical trials, no literature, and no plausible mechanistic link — it is Evidence Level L5, model-prediction-only. There is no basis to advance this specific indication beyond hypothesis generation.

To proceed, the following is needed:

TFDA/Medsafe package insert (warnings, contraindications) — currently blocking (DG001)
Sulfasalazine mechanism of action data from DrugBank — currently high-priority gap (DG002)
Preclinical or mechanistic studies specifically linking sulfasalazine's pharmacology to skeletal/connective-tissue developmental pathways, if this indication is to be pursued further

Note: This evidence pack also contains two other TxGNN predictions with materially stronger support that may warrant separate evaluation — Osteoarthritis (rank 5, L3, multiple preclinical studies, Research Question stage) and Spondyloarthropathy susceptibility (rank 8, L3, Proceed with Guardrails, supported by NAT2-pharmacogenomic and clinical-guideline context for peripheral spondyloarthritis). Given sulfasalazine's established role in inflammatory arthritis, these two candidates are more actionable repurposing directions than the top-ranked rare-disease prediction reported above.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.